UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Solventum Co. (NYSE:SOLV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Solventum Co. (NYSE:SOLV) by 0.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,053,771 shares of the company’s stock after buying an additional 3,745 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Solventum were worth $73,469,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Deseret Mutual Benefit Administrators purchased a new position in shares of Solventum in the 2nd quarter valued at about $25,000. Hollencrest Capital Management purchased a new position in Solventum in the second quarter worth approximately $25,000. Richard W. Paul & Associates LLC purchased a new position in Solventum in the second quarter worth approximately $26,000. Family Firm Inc. purchased a new stake in shares of Solventum in the 2nd quarter valued at approximately $26,000. Finally, Copeland Capital Management LLC purchased a new stake in shares of Solventum in the 3rd quarter valued at approximately $26,000.

Solventum Stock Up 0.6 %

Shares of SOLV opened at $71.95 on Tuesday. The company’s 50 day simple moving average is $70.55 and its 200-day simple moving average is $62.58. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on SOLV shares. Wells Fargo & Company lowered their target price on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. BTIG Research assumed coverage on Solventum in a research report on Thursday, September 5th. They set a “neutral” rating for the company. Piper Sandler raised their target price on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Morgan Stanley upped their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, Wolfe Research started coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and a consensus target price of $68.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.